Greenland Bio-Pharmaceutical Co., Ltd.
2025 Audit Committee Report on Supervision of Duty Performance
In accordance with the "Administrative Measures for the Selection of Accounting Firms by State-owned Enterprises and Listed Companies," the "Articles of Association" of Greenland Bio-Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), and the "Articles of Association of the Board of Directors Audit Committee," etc., the Company's Board of Directors Audit Committee has conscientiously performed its duties with diligence and responsibility. The following is a report on the supervision of the audit committee over the 2025 audit institution's performance of its duties:
I. Basic Information of the 2025 Annual Audit Accounting Firm
(I) Basic Information of the Accounting Firm
Lixin Certified Public Accountants (Special General Partnership) (hereinafter referred to as "Lixin") was founded by Dr. Pan Xulun, a renowned Chinese accounting scholar, in Shanghai in 1927. It was re-established in 1986 and became the first special general partnership accounting firm in China to complete its restructuring in 2010. Its registered address is in Shanghai, and its chief partner is Mr. Zhu Jiandi. As of the end of 2025, Lixin has 300 partners, 2,523 certified public accountants, and a total of 9,933 employees. Among them, 802 certified public accountants have signed audit reports for securities service businesses.
(II) Procedures for Appointing the Accounting Firm
On November 25, 2025, the eighth meeting of the Fifth Board of Directors Audit Committee of the Company deliberated and approved the "Proposal on the Proposed Re-appointment of the 2025 Audit Institution." It was agreed to appoint Lixin as the Company's 2025 audit institution, and the relevant matters were submitted to the Company's Board of Directors for deliberation.